Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis

Abstract

AbstractThis study aimed to explore the potential mechanism by which sulfasalazine (SAS) inhibits esophageal cancer cell proliferation. A cell counting kit‐8 (CCK‐8) assay was used to detect the effect of SAS (0, 1, 2, and 4 mM) on the proliferation of TE‐1 cells. Subsequently, TE‐1 cells were divided into control group, SAS group, SAS + ferrostatin‐1 (ferroptosis inhibitor) group, and SAS + Z‐VAD (OH)‐FMK (apoptosis inhibitor) group, and cell proliferation was measured using a CCK‐8 assay. Real‐time quantitative polymerase chain reaction and western blotting were used to determine the expression of solute carrier family member 7 11 (SLC7A11, also called xCT), glutathione peroxidase 4 (GPX4), and acyl‐CoA synthase long‐chain family member 4 (ACSL4) in TE‐1 cells. Measurement of ferroptosis in TE‐1 cells was achieved by flow cytometry. Compared with the control group (0 mM SAS), the proliferation of TE‐1 cells was significantly inhibited by different concentrations of SAS for different time lengths, and 4 mM SAS treatment for 48 h could obtain the maximum inhibition rate (53.9%). In addition, SAS treatment caused a significant decrease in the mRNA and protein expression of xCT and GPX4, and a significant increase in ACSL4 expression in TE‐1 cells treated with SAS. Flow cytometry results showed that the ferroptosis level was significantly increased after SAS treatment. However, the activation of ferroptosis by SAS was partially eliminated by treatment with ferrostatin‐1 or Z‐VAD (OH)‐FMK. In conclusion, SAS inhibits the proliferation of esophageal carcinoma cells by activating the ferroptosis pathway.